fda banning semaglutide Compounded Manufacturing Ban Minnesota doctor says FDA weight-loss

Referrals to specialists may be necessary based on the suspected cause: endocrinology for endocrine disorders or complex hypoglycemia, sleep medicine for suspected sleep apnea, hematology/oncology for suspected malignancy, or infectious disease for chronic infections

It carries an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease

H Cao, A Baranova, Q Zhao, F Zhang (2024)

Methods: We did a 40-week, randomised, active-controlled, parallel-group, double-blind, phase 3B trial (SUSTAIN FORTE) at 125 outpatient clinics in ten countries

doi: 10.3390/cancers14215444, 82

While widespread patient access is not anticipated until a potential FDA approval in 2026 or later, there are structured pathways to access investigational drugs before they reach the market